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Abstract
Malaria remains one of the world’s greatest killers and a vaccine is urgently required. There are no established correlates of
protection against malaria either for natural immunity to the disease or for immunity conferred by candidate malaria
vaccines. The RTS,S/AS02A vaccine offers significant partial efficacy against malaria. mRNA expression of five key cytokines
interferon-gamma (IFN-c), monokine induced by gamma (MIG), interleukin-10 (IL-10), transforming growth factor-b (TGF-b)
and forkhead box P3 (FoxP3) in peripheral blood mononuclear cells were measured by real-time RT-PCR before and after
vaccination with RTS,S/AS02A and Modified Vaccinia virus Ankara encoding the circumsporozoite protein (MVA-CS) in
healthy malaria-naı ¨ve adult volunteers. The only significant change was in IFN-c mRNA expression, which was increased
seven days after vaccination (P=0.04). Expression of MIG mRNA seven days after vaccination correlated inversely with time
to detection of parasites by blood film in an experimental sporozoite challenge (r=0.94 P=0.005). An inverse relationship
was seen between both TGF-b1 and IL-10 mRNA at baseline and the anti-circumsporozoite IgG antibody response
(r=20.644 P=0.022 and r=20.554 P=0.031 respectively). This study demonstrates the potential for MIG expression as a
correlate of protection against malaria. Baseline levels of the regulatory cytokines TGF-b and IL-10 inversely correlated with
antibody levels post vaccination and warrant further studies to improve understanding of individual differences in response
to vaccination.
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Introduction
A vaccine for malaria is urgently required, but clear correlates of
immunity against malaria have not been established. A better
understanding of immune markers induced by candidate malaria
vaccines would greatly enhance vaccine development, immunogenic-
ity monitoring and estimation of vaccine efficacy in the field. Neither
IFN-c secretion, nor antibody levels correlate consistently with
protection from malaria [1]. Many studies of T-cell effector function
in mice [2], malaria-exposed humans [3] and vaccinated malaria-
naı ¨ve populations [4] have underlined the complexity and diversity of
T-cell immunity. Antibodies, CD8+ T cells, CD4+ T cells, IFN-c,I L -
12 and nitric oxide (NO) have all been implicated as critical effectors
in protection against pre-erythrocytic stage malaria [5]. There is
increasing evidence that, in addition to antibodies, protection from
blood-stage malaria is determined by the balance of pro and anti-
inflammatory immune responses induced by the parasite [3,6–9].
The only candidate vaccine to demonstrate reproducible
efficacy in the field is RTS,S, a pre-erythrocytic stage vaccine
based on the P. falciparum circumsporozoite (CS) protein and
administered in either the proprietary adjuvant AS02A (RTS,S/
AS02A), or more recently in adjuvant AS01E (RTS,S/AS01E).
RTS,S/AS02A induces strong IgG antibody responses to the
NANP repeat region of the circumsporozoite antigen, as well as
some CD4+ T-cell responses [4,10]. This vaccine has been shown
to confer protection against clinical malaria in a significant
proportion of healthy non-immune U.S. adults in challenge studies
[11], and partial protection in field studies [12–15] More recently
a phase IIb trial of RTS,S administered in the adjuvant AS01E in
Kenyan children aged 5–17 months reported an efficacy against
clinical malaria of 53% [16] for eight months of follow-up and
phase III trials are underway across Africa.
A clinical trial conducted in the UK [17] aimed to enhance the
immunogenicity of RTS,S/AS02A alone by combining it in a
prime-boost strategy with MVA that encoded the circumspor-
ozoite (CS) protein. T-cell responses as measured by IFN-c ex vivo
ELISPOT assays were induced, but the responses were low to
moderate, with heterologous boosting yielding only small incre-
ments in T-cell immunogenicity and no enhancement in antibody
responses. No increase in protection against sporozoite challenge
compared to RTS,S/AS02A alone was seen [16]. Nevertheless, as
a total of four volunteers, two from each arm of the study,
developed sterile protection this trial provided an opportunity to
monitor responses to the circumsporozoite antigen before and
after vaccination with RTS,S/AS02A in an effort to identify
immune correlates of protection.
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up-regulation of TGF-b1, FoxP3 and the generation of Treg cells
along with faster rates of parasitic growth in subjects infected with
P. falciparum [8]. We have also demonstrated that MIG (CXCL9),
as a marker of bioactive IFN-c, is useful for measuring vaccine
induced pro-inflammatory immune responses [18] in line with a
previous report [19].We hypothesised that levels of anti-inflam-
matory and pro-inflammatory cytokines may be associated with
vaccine efficacy and we have used real time RT-PCR to monitor
changes in TGF-b1, FoxP3, IL-10, IFN-c and MIG in malaria-
naı ¨ve adults receiving the candidate malaria vaccines RTS,S/
AS02A and MVA-CS in a clinical trial. Although the number of
subjects included in the clinical trial with RTS,S/AS02A and
MVA-CS was small, such exploratory studies with real time RT-
PCR may help to guide the selection of immune markers for
analysis in larger efficacy trials.
Results
Vaccine induced changes in gene expression and
correlation with protection from malaria challenge
In this trial subjects received two doses of the RTS,S/AS02A (R
vaccine) vaccine (R vaccine) (GSK Biologicals, Rixensart, Belgium)
and one dose of MVA-CS (M vaccine) (Oxford University,
Oxford, UK). 28 days after the final immunisation the efficacy of
the vaccine schedule (either MRR or RMM) was assessed in twelve
of the volunteers by experimental sporozoite challenge.
Gene expression studies were performed using cryopreserved
samples from subjects before and after vaccination (Day 0, the day
of first vaccination, and 7 and 28 days after the final vaccination).
For each cytokine studied expression levels relative to the
housekeeping gene HPRT were determined for both CS
stimulated (Figure 1) and unstimulated PBMCs (Figure 2), and
Figure 1. The Expression of Cytokines in CS-stimulated Cells Before and After Vaccination. Expression of IFN-c, MIG, TGF-b1, FoxP3 and
IL-10 was measured by real-time RT-PCR in total PBMCs following 12 hour culture with the vaccine antigen CS in subjects who received vaccination
with RTS,S/AS02A and MVA-CS. Results are expressed as copy number relative to the housekeeping gene HPRT. Median values (9 subjects) are shown.
Vac+7= seven days after the final vaccination, Vac+28=28 days after the final vaccination, each subject received two doses of RTS,S/AS02A and one
dose of MVA-CS. A) IFN-g mRNA, B) MIG mRNA, C) TGF-b1 mRNA, D) FoxP3 mRNA, E) IL-10 mRNA and F) Correlation of MIG mRNA expression at day 7
with days to parasitemia following sporozoite challenge, n=6–12.
doi:10.1371/journal.pone.0012557.g001
Malaria Vaccine Immunogenicity
PLoS ONE | www.plosone.org 2 September 2010 | Volume 5 | Issue 9 | e12557the fold change in expression level in the CS-stimulated cells
compared to the unstimulated cells at each timepoint determined
(Table 1).
In the CS stimulated PBMC the only gene with a significant
median increase in expression following vaccination was IFN-c,
P=0.04 (Figure 1A). MIG, FoxP3 and IL-10 were non-significantly
Figure 2. The Expression of Cytokines in Unstimulated Cells Before and After Vaccination. Expression of IFN-c, MIG, TGF-b1, FoxP3 and
IL-10 was measured by real-time RT-PCR in total PBMCs following 12 hour culture in media only in subjects who received vaccination with RTS,S/
AS02A and MVA-CS. Results are expressed as copy number relative to the housekeeping gene HPRT. Median values (6–12 subjects) are shown.
Vac+7= seven days after the final vaccination, Vac+28=28 days after the final vaccination, each subject received two doses of RTS,S/AS02A and one
dose of MVA-CS. A) IFN-g mRNA, B) MIG mRNA, C) TGF-b1 mRNA, D) FoxP3 mRNA, E) IL-10 mRNA and F) Correlation of MIG mRNA expression at day 7
with days to parasitemia following sporozoite challenge.
doi:10.1371/journal.pone.0012557.g002
Table 1. Foldchange of Gene Expression at Each Timepoint in CS-Stimulated Cells Compared to Unstimulated Cells.
Day 0 Vac+7 Vac+28
IFN-c median foldchange (range) 0.9 (0.4–1.8) n=12 2.7 (1.1–29.7) n=12 1.5 (0.8–3.7) n=9
FoxP3 median foldchange (range) 0.8 (0.6–1.5) n=12 1.5 (0.7–2.5) n=9 0.9 (0.7–3.3) n=10
MIG median foldchange (range) 3.4 (0.2–7.7) n=12 7.9 (0.6–25.4) n=9 1.4 (0.3–11.2) n=10
IL-10 median foldchange (range) 0.8 (0.2–2.6) n=11 0.6 (0.1–1.8) n=8 (0.6–2.0) n=11
TGF-b1 median foldchange (range) 1.1 (0.5–1.8) n=12 (0.0–1.8) n=11 1.1 (0.8–2.2) n=12
Day 0= baseline prior to vaccination.
Vac+7= seven days after the final vaccination.
Vac+28=28 days after the final vaccination.
doi:10.1371/journal.pone.0012557.t001
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and E) and TGF-b1 appeared unchanged (Figure 1C). In the
unstimulated PBMC there was no significant change in the median
expression ofanygene studied (Figure2).Wehavepreviouslyshown
that in this clinical trial neither IFN-c, measured by ex vivo
ELISPOT, nor anti-CS IgG antibodies correlated with protection
against malaria in a sporozoite challenge [17]. In our challenge
studies volunteers are closely followed and daily blood films are
taken for 21 days following sporozoite challenge when sterile
protection is assumed. We are therefore able to identify the day
upon which a challenged volunteer becomes blood film positive and
to assesswhether thevaccine group have a delayinthedevelopment
of detectable parasitemia when compared to the control group. As
we follow volunteers for a maximum of 21 days, volunteers with
sterile protection are assigned a delay to parasitemia of 21 days for
statistical analysis. In the current study, When mRNA data was
examined for correlation with delay to parasitemia, we found that
MIG mRNA in unstimulated PBMC at the 7 day post vaccination
time point correlated with protection from sporozoite challenge
(r=0.94 P=0.005, Figure 2F). A similar trend was seen in CS
stimulated PBMC, althoughthisdidnot reachstatistical significance
(r=.794 P=.059, Figure 1F).
The gene with the greatest fold change increase in expression
both before and following vaccination was MIG, followed by IFN-c
then FoxP3 (Table 1). There was no fold increase in expression of
TGF-b1 or IL-10. The fold change in expression of none of these
cytokines showed any correlation with protection against malaria in
the sporozoite challenge.
Correlation of gene expression with IFN-c ex vivo
ELISPOT and anti-CS IgG antibody responses
There was no correlation of the day 7 IFN-c ELISPOT response
with MIG mRNA expression in either CS stimulated or
unstimulated PBMC and no correlation of IFN-c ELISPOT with
protection from malaria. None of the cytokines measured by RT-
PCRinCS stimulated PBMCcorrelated with theIFN-c ELISPOT.
There was an inverse relationship between TGF-b1 mRNA in
unstimulated PBMC at baseline and the anti-CS IgG antibody
response measured on the day of malaria challenge r=20.644
P=0.022 (Figure 3A). TGF-b1 mRNA at day 7 also correlated
Figure 3. Inverse Correlation between Anti-inflammatory Cytokines and Antibody Response on the Day of Malaria Challenge. The
anti-CS IgG antibody response on the day of malaria challenge induced by vaccination with RTS,S and MVA-CS inversely correlates with the anti-
inflammatory cytokines TGF-b1 and IL-10 measured in unstimulated PBMC. A) TGF-b1 at baseline inversely correlates with anti-CS IgG measured on
day of challenge r=20.644 P=0.022. B) TGF-b1 at day 7 inversely correlates with anti-CS IgG measured on day of challenge, r=20.670 P=0.009. C)
IL-10 mRNA at baseline inversely correlates with anti-CS IgG measured on day of challenge r =20.554 P=0.031. D) IL-10 mRNA at day 28 inversely
correlates with anti-CS IgG measured on day of challenge r=20.762 P=0.005. The volunteers with sterile protection are indicated by open circles
and triangles indicate volunteers who did not enter the challenge study. Correlations were performed using Spearman’s two-tailed test, n=9–12.
doi:10.1371/journal.pone.0012557.g003
Malaria Vaccine Immunogenicity
PLoS ONE | www.plosone.org 4 September 2010 | Volume 5 | Issue 9 | e12557with anti-CS IgG antibodies on the day of malaria challenge,
r=20.670 P=0.009 (Figure 3B). An inverse relationship was also
seen for IL-10 at baseline and anti-CS IgG antibody on the day of
challenge in unstimulated PBMC r=20.554 P=0.031
(Figure 3C), and similarly for IL-10 at day 28 and anti-CS IgG,
r=2.762 P=.005 (Figure 3D).
Correlation between MIG and pro- and anti-inflammatory
cytokine mRNA expression
As MIG mRNA was associated with protection from malaria we
searched for correlations between MIG mRNA and the remaining
cytokines in our data set. In the CS stimulated PBMC the
expression of IFN-c mRNA correlated with the expression of MIG
mRNA, r=0.851 P=0.004 (Figure 4A). For this analysis samples
were available from only two of the four volunteers with sterile
protection. Both of the volunteers with sterile protection had a
higher proportion of MIG mRNA compared to IFN-c mRNA.
In the unstimulated PBMC the only cytokine to correlate with
MIG expression was IL-10. There was an inverse relationship
between the expression of IL-10 at baseline and MIG at baseline
(Figure 4B), day 7 (Figure 4C) and day 28 (Figure 4D). At the day
7 timepoint (Figure 4C) both of the volunteers with sterile
protection had a higher proportion of MIG mRNA when
compared to IL-10 mRNA. Although the numbers are small
these results indicate that MIG expression may be influenced by
both IFN-c and IL-10 and that high MIG expression may be a
marker of sterile protection.
Correlation of IL-10 with FoxP3 and TGF-b1 mRNA
expression
Although in this study there were insufficient cells to confirm the
presence of regulatory T cells by flow cytometry analysis and cell
depletion studies we were able to look for associations between the
anti-inflammatory cytokines IL-10 and TGF-b1 and the regula-
tory T cell transcription factor, FoxP3. IL-10 expression correlated
with FoxP3 expression in unstimulated cells in all time points
tested (Figure 5A, B and C). IL-10 expression also correlated with
TGF-b1 at day 28 following vaccination with RTS,S and
MVA-CS.
Discussion
Malaria vaccine development is at an exciting stage with both
antibody-targeted and T cell-targeted pre-erythrocytic vaccines
showing partial protection in humans [20]. However, frustratingly
the most effective vaccine candidate RTS,S still only shows about
50% efficacy in the most successful phase IIa efficacy trials [21],
and varying levels of protection in IIb field trials [16]. A better
understanding of how some vaccine recipients are better protected
than others could be crucial to developing a higher efficacy
vaccine. Real time RT-PCR is an emerging method for measuring
both pro-inflammatory and anti-inflammatory immune responses
in humans and shows real potential for the monitoring of vaccine
trials where cell numbers are limited and immune responses are
often low. Using real time RT-PCR to monitor changes in gene
Figure 4. The Correlation of MIG mRNA with Pro- and Anti-inflammatory Cytokines. A) In CS stimulated PBMC the expression of MIG
mRNA at day 7 correlated with the expression of IFN-g mRNA at day 7 r=0.851 P=0.004. In unstimulated PBMC IL-10 mRNA at baseline inversely
correlated with B) baseline MIG mRNA r=20.497 P=0.05. C) Day 7 MIG mRNA, r=20.787 P=0.006. D) Day 28 MIG mRNA, r=20.657 P=0.02. The
volunteers with sterile protection are indicated by open circles and triangles indicate volunteers who did not enter the challenge study. Correlations
were performed using Spearman’s test, n=9–12.
doi:10.1371/journal.pone.0012557.g004
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RTS,S/AS02A and MVA-CS we have found that mRNA
expression of pro and anti-inflammatory cytokine responses in
unstimulated PBMC are associated with vaccine immunogenicity
and protection from malaria in a sporozoite challenge model. The
associations we have found are strongest in unstimulated PBMC
and in the timepoint seven days following vaccination.
Previous studies have reported MIG detection to be a more
sensitive measure of immunogenicity than the measurement IFN-c
by ELISPOT, ELISA or flow cytometry [19,22,23]. MIG has also
been shown to be important for protection from Trypanosoma cruzi
infection in mice [24] and is associated with disease severity in
human tuberculosis [25]. MIG is induced by IFN-c and mediated
via the JAK-STAT signalling pathway [26] and is therefore a
marker of bioactive IFN-c and functional JAK-STAT signalling.
In CS stimulated PBMC there was a correlation between MIG
and IFN-c mRNA, although in the two volunteers with sterile
protection there was more MIG relative to IFN-c. This may
indicate either higher levels of bioactive IFN-c or greater JAK-
STAT signalling in the protected volunteers when compared to
the rest of the challenge group. IL-10 is an anti-inflammatory
cytokine with the primary function of regulating immune
responses by activation of the macrophage JAK-STAT pathway
[27]. Activation of this pathway through the IFN-c receptor is pro-
inflammatory and leads to the expression of IFN-c induced genes,
including MIG, whereas activation through the IL-10 receptor
leads to immune regulation. We saw a reciprocal relationship
between the expression of MIG and IL-10 mRNA at all time
points studied and have found that MIG expression 7 days
following final vaccination correlated inversely with time to
detection of parasites by blood film in a human sporozoite
challenge model. The correlation of MIG with delay to blood film
positivity supports the hypothesis that T cells and bioavailable
IFN-c immune responses are important in host defence against the
parasite, with previous studies demonstrating the correlation of
MIG and bioavailable IFN-c in humans as detected by RT-PCR
and flow cytometry [18,19].
Although in our study anti-CS IgG antibodies did not correlate
with protection from disease, immune protection from malaria is
complex and T cells as well as antibodies have been shown to be
important [1,5,21,28,29]. There was no evidence that the addition
of MVA-CS to the RTS,S/AS02A regimen enhanced the efficacy
of RTS,S/AS02A. RTS,S/AS02A is a known powerful inducer of
an antibody response [30,31] and analysis of the immune
responses from subjects in this study showed a strong antibody
response and only a modest T-cell responses [17]. We have found
that both IL-10 and TGF-b1 mRNA inversely correlate with the
levels of anti-CS IgG antibodies following vaccination with RTS,S
Figure 5. The Correlation of IL-10 expression with FoxP3 and TGFb1 mRNA Expression. For the A) baseline (r=0.557 P=0.030), b) 7 days
following vaccination (r=0.695 P=0.019) and C) 28 days following vaccination time points (r=0.554 P=0.048) IL-10mRNA expression correlates with
FoxP3 expression. At the 28 days time point D) IL-10 mRNA also correlates with TGF-b1 mRNA expression (r=0.642 P=0.023). The volunteers with
sterile protection are indicated by open circles and triangles indicate volunteers who did not enter the challenge study. Correlations were performed
using Spearman’s one-sided test, n=9–12.
doi:10.1371/journal.pone.0012557.g005
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inflammation and immunoregulation and is a potent inhibitor of B
cell maturation, proliferation, IgM and IgG production in the
mouse [32,33] and has also been shown to inhibit IgG production
in humans [34,35]. TGF-b1 has also been demonstrated to play a
key role in the induction and maintenance of peripheral regulatory
T cells in humans [36–38]. The inverse relationship found
between TGF-b1 levels and antibody response on day of challenge
is of interest. Exposure to enteric bacteria is likely to result in the
development of regulatory lymphocytes as proposed in the hygiene
hypothesis [39] and children with food allergy have reduced TGF-
b+ T-cells in the duodenal mucosa [40]. There is also evidence of
a strong genetic contribution to circulating TGF-b1 levels [41].
There is a wide variation in TGF-b levels within and between
populations, for example levels of duodenal TGF-b+cells in rural
Gambian infants are up to ten times higher than in UK controls
[42]. We hypothesise that levels of TGF-b may be related to
immune responses to vaccination. In a murine model of malaria a
relationship between response to vaccination, gut parasite
infestation and TGF-b1 levels has been reported [43]. Parallel
studies in our laboratory have demonstrated down-regulation of
TGF-b1 and increased IFN-c ELISPOT responses following
boosting of BCG vaccinated subjects with the novel tuberculosis
vaccine MVA-85A [44]. Due to limited cell numbers we were
unable to confirm if regulatory T cells were influencing the vaccine
induced immune response or protection from disease.
Although protection induced by vaccination with RTS,S is
partial it remains the best performing candidate malaria vaccine in
the world. There has been no immune correlate of protection
identified for RTS,S to date although both antibodies, and
possibly also T cells, are thought to be important for protection
[10–13,45]. Our results support the view that a functional IFN-c
immune response is important for protection induced by RTS,S
although whether this would work by a direct effect of cellular
immunity at the liver-stage or by modulating the quality of
protective antibodies induced remains unclear. The role of the
MVA-CS vaccine cannot be fully ascertained in this study. MVA-
CS neither induced nor boosted antibody responses and there was
no evidence of improvement in efficacy compared to RTS,S used
alone in other studies [17]. IL-10 and TGF-b1 may play a dual
role in the attenuation of both protective T cell and IgG antibody
responses induced by vaccination [46], and suggest pathways for
the next generation of vaccines to target to enhance responses.
This study was based on mRNA measurement in relatively
small cell numbers, giving potential for development of monitoring
assays using fingerprick blood samples suitable for field trials. An
immune correlate of protection would greatly facilitate the
development and testing of new malaria vaccines. Our findings,
in such a small dataset of twelve subjects, need to be confirmed in
a larger challenge study cohort and in a field setting and more
detailed analysis of the pathways involved is required. In particular
the impact of baseline IL-10 and TGF-beta levels on the induction
of antibodies in African populations could be assessed by
monitoring volunteer samples collected prior to vaccination with
RTS,S and other candidate malaria vaccines. The feasibility of
mRNA profiling to assess immune responses in an African vaccine
trial has been demonstrated [47]. Factors affecting the develop-
ment of protective immune responses following vaccination with
RTS,S/AS02A are of considerable interest to the vaccine
community as further elucidation of these mechanisms could hold
the key to understanding why some individuals acquire effective
immunity after vaccination to life-threatening infections while
others remain devastatingly vulnerable, opening doors to design-
ing the next generation of highly effective malaria vaccines.
Materials and Methods
Clinical Trial
Eighteen healthy adult malaria-naı ¨ve volunteers in Oxford, UK
participated in a vaccine trial as described previously [17]. The
study received ethical approval from the Oxfordshire Research
Ethics Committee and the Human Subjects’ Protection Commit-
tee at PATH (Program for Appropriate Technology in Health) in
Seattle, WA, USA. All participants gave written, informed consent
prior to participation. The trial was conducted according to Good
Clinical Practice guidelines, was externally monitored, and was
approved by the UK Medicines and Healthcare products
Regulatory Agency (MHRA). Subjects received two doses of the
RTS,S/AS02A vaccine (GSK Biologicals, Rixensart, Belgium)
and one dose of MVA-CS (Oxford University, Oxford, UK). 28
days after the final immunisation the efficacy of the vaccine
schedule was assessed in twelve of the volunteers by experimental
sporozoite challenge, whereby the volunteers were exposed to the
bites of five laboratory-reared mosquitoes infected with the
chloroquine-sensitive 3D7 strain of Plasmodium falciparum. In this
study four out of twelve vaccinated subjects demonstrated
complete (sterile) protection against clinical malaria (no parasit-
emia detectable within 21 days of challenge). For the twelve
subjects as a group number of days to parasitemia was used to
assess partial or complete efficacy against malaria.
Antibody monitoring
Anti-CS repeat region antibody concentrations were measured
in serum at the Walter Reed Army Institute of Research by Dr. V.
Ann Stewart by specific IgG ELISA to a recombinant protein
containing 32 P. falciparum derived tetrapeptide repeat sequences
MDP-[(NANP)15NDVP]2LR [48] and expressed as GMCs
(Geometric Mean Concentrations) in mg/ml. Antibodies were
measured at baseline, 28 days after each vaccine dose, and three
months after the malaria challenge.
PBMC separation
Peripheral blood mononuclear cells (PBMC) were isolated by
density gradient, using Lymphoprep (Axis-Shield, Oslo, Norway),
resuspended in culture media comprising RPMI 1640 (Sigma-
Aldrich, Poole, Dorset, UK) with 10% heat-inactivated normal human
AB sera (UK Blood Bank Service, National Health Service, UK), 1000 U/
ml penicillin-streptomycin and 2 mM L-glutamine (both Invitrogen
Life Technologies, Paisley, UK) and stored in 10% DMSO-Foetal Calf
Serum (both Sigma-Aldrich, Poole, Dorset, UK) in liquid nitrogen until
required.
Cell stimulation for gene expression studies
Cells for gene expression studies by RT-PCR were stimulated
with one peptide pool (consisting of 61 separate 15-mer peptides
designed to span the CS protein) for 12 hours overnight at a
concentration of 2 mg/ml. For each sample, 1 million cells in
100 ml were plated out in each of two wells of a 96-well U-
bottomed plate and incubated at 37uC for 5 hours prior to
stimulation. This 5 hour resting period prior to stimulation had
been shown to produce optimal results in terms of RNA yield and
antigen-specific responses. 100 ml of either peptide pool or media
was then added to each well to commence the 12 hour stimulation
at 37uC.
RNA extraction and RT-PCR
RNA extraction and reverse transcription of RNA into cDNA
were performed using the RNeasy Mini-kit and the Omniscript kit
(both Qiagen, Crawley, West Sussex, UK) according to the manufac-
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PCR was performed using the Lightcycler 2.0 (Roche, Basel,
Switzerland) carousel-based system using Quantitect SYBR Green
Mastermix (Qiagen, Crawley, West Sussex, UK). All reactions were
performed in duplicate with two negative controls per run.
Samples were run using the Lightcycler programme, with a 15-
minute incubation at 95uC followed by 45 thermal cycles,
consisting of a 15-second denaturation step at 94uC, then a 20-
second annealing step at 60uC, and a 20-second extension step at
72uC after which fluorescence was read. Data were produced as
amplification plots with fluorescence plotted against number of
cycles. The CT (threshold cycle) value for each sample was
calculated with the threshold set during the log-linear phase of
amplification using the ‘‘Fit points’’ method, where the noiseband
for each experiment was manually adjusted to 0.1 fluorescence
units. A melt curve programme was performed at the end of each
to check the melting points of the products detected for
identification and specificity.
The primer sequences used were TGF-b1F :5 9-GGACAT-
CAACGGGTTCACTA-39, TGF-b1R :5 9-CCGGTTCATGC-
CATGAATGG-39, IFN-c F: 59-ATTCGGTAACTGACTTG-
AATGTCC-39, IFN-c R: 59-CTCTTCGACCTCGAAACAGC-
39, MIG F: 59-GCATCATCTTGCTGGTTCTGATTGG-39,
MIG R: 59-GCGACCCTTTCTCACTACTGGGGT-39, FoxP3
F: 59-CACTTACAGGCACTCCTCCAGG-39, FoxP3 R: 59-
CCACCGTTGAGAGCTGGTGCAT-39, IL-10 F: 59-GGCCG-
TGGAGCAGGT-39 and IL-10 R: 59-CACTCATGG CTTTG-
TAGATGCC-39.
Statistical Analysis
The number of subjects included in this exploratory study is
small. Significant findings, while useful for observing trends in the
data, are prone to error and must be confirmed in larger studies.
Real time RT-PCR data were interpreted using standard curves
derived for each gene. To normalise for cell number, the copy
number for each gene of interest was expressed as a ratio relative
to the copy number of the housekeeping gene HPRT for that
sample. As the data were not normally distributed non-parametric
tests were used. For analysis of difference between two related
samples Wilcoxon’s signed rank test for significance was used. For
testing of significance of correlations the two-tailed Spearman’s
Rank test was used unless otherwise stated. A P value of less than
0.05 was considered significant. The data was represented
graphically using GraphPad Prism version 4 software to plot
best-fit linear regression lines.
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